Zoetis (ZTS) PT Set at $90.00 by Cantor Fitzgerald

Cantor Fitzgerald set a $90.00 price target on Zoetis (NYSE:ZTS) in a report published on Thursday. The firm currently has a buy rating on the stock.

A number of other equities analysts have also weighed in on ZTS. Stifel Nicolaus reiterated a buy rating and issued a $65.00 price target on shares of Zoetis in a report on Tuesday, October 24th. BMO Capital Markets set a $65.00 target price on shares of Zoetis and gave the company a hold rating in a report on Wednesday, October 25th. BidaskClub lowered shares of Zoetis from a buy rating to a hold rating in a report on Thursday, October 26th. Zacks Investment Research lowered shares of Zoetis from a buy rating to a hold rating in a report on Wednesday, November 1st. Finally, Morgan Stanley lifted their target price on shares of Zoetis from $61.00 to $70.00 and gave the company an equal weight rating in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $79.83.

Zoetis (ZTS) opened at $79.73 on Thursday. The firm has a market cap of $38,850.00, a price-to-earnings ratio of 36.57, a price-to-earnings-growth ratio of 1.71 and a beta of 1.07. Zoetis has a 1-year low of $52.25 and a 1-year high of $81.40. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 15th. The company reported $0.69 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.03. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.40 billion. Zoetis had a net margin of 16.28% and a return on equity of 65.83%. Zoetis’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same quarter last year, the business earned $0.47 EPS. equities research analysts expect that Zoetis will post 3.02 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 1st. Shareholders of record on Friday, April 20th will be issued a $0.126 dividend. The ex-dividend date of this dividend is Thursday, April 19th. This represents a $0.50 dividend on an annualized basis and a yield of 0.63%. Zoetis’s dividend payout ratio is currently 22.94%.

Hedge funds have recently modified their holdings of the business. Harel Insurance Investments & Financial Services Ltd. acquired a new position in Zoetis in the 4th quarter worth $108,000. We Are One Seven LLC acquired a new position in Zoetis in the 4th quarter worth $120,000. Premia Global Advisors LLC acquired a new position in Zoetis in the 4th quarter worth $122,000. Icon Wealth Partners LLC acquired a new position in Zoetis in the 4th quarter worth $127,000. Finally, Steward Partners Investment Advisory LLC acquired a new position in Zoetis in the 3rd quarter worth $114,000. Hedge funds and other institutional investors own 93.72% of the company’s stock.

WARNING: This piece was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://sportsperspectives.com/2018/02/19/zoetis-zts-pt-set-at-90-00-by-cantor-fitzgerald.html.

Zoetis Company Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply